Nasus Pharma Ltd. (NSRX)
Nasus Pharma Ltd. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Tel Aviv, TA, IL. The stock last traded at $3.24, down 2.16% on the session, giving a market capitalisation of $27.9M. On trailing twelve-month figures it carries a trailing P/E of -19.05, a net margin of 0.0%. Its beta of 3.96 implies it has historically moved more than the broad market.
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Nasus Pharma Ltd. is most often compared with the following Healthcare names: